Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...

BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Asad Haider, head of the healthcare business unit within Goldman Sachs Research, now forecasts the market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, to ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Meanwhile, UBS maintained a Buy rating on Eli Lilly, setting a price target of $1,050, and BMO Capital reiterated an Outperform rating with a $900 price target following the SiteOne deal.

Meanwhile, Eli Lilly has also made a strategic move by agreeing to acquire SiteOne Therapeutics in a deal valued at up to $1 billion. This acquisition aims to enhance Lilly’s non-opioid pain ...

Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other ...